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Introduction
In many European countries measles is still a cause of great
public health concern.   Outbreaks of the disease are still
occurring because the degree of vaccination coverage required
to interrupt transmission has not yet been achieved.  Many
countries have started to implement measles elimination
strategies.  These are primarily based on attaining a very high
coverage of measles vaccination and strengthening measles
surveillance systems.
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Current situation
Measles is an acute, highly contagious viral disease capable
of producing epidemics.  It remains the leading cause of vaccine-
preventable deaths in children worldwide.  Despite the
availability of an effective measles vaccine for more than 30
years, measles has still not been controlled in many parts of the
world.  In many European countries it is still a cause of great
public health concern1-4.  In 2002, several European countries
have reported measles outbreaks.  The largest one occurred in
the Campania region in Southern Italy where measles
vaccination coverage is poor.  An estimated 24,000 children
between 0-14 years of age suffered from measles between
January to May 2002.  In the same period, 368 persons were
hospitalised with measles.  Of these, 63 had pulmonary
complications, 13 had encephalitis, and three died 3.  In the first
five months of 2003, 1217 cases have been reported in a new
epidemic in the southern Italian regions of Abruzzo, Calabria
and Puglia5.  In Switzerland, 387 cases were recorded in three
separate outbreaks during February and March of this year 6.
The disease continues to spread because the degree of
vaccination coverage required to interrupt transmission has not
yet been achieved. The changing epidemiology of measles,
therefore, presents challenges for the European region as
outbreaks still occur where there is an accumulation of
susceptible children and young adults.
Measles elimination initiatives
Following the successful interruption of wild poliovirus
transmission in the European Region, many countries are eager
to move towards targeting measles elimination.  Many European
countries are strengthening measles surveillance and have
already started the implementation of elimination strategies,
or set elimination goals. The World Health Organization
Regional Office for Europe has developed a strategy to stop the
indigenous transmission of measles in the European region by
2010 and to prevent congenital rubella infection7, 8.  WHO
recommends a combination of the following activities for
reaching these goals:
1. Achieving and sustaining very high coverage with two doses
of measles vaccine through high-quality routine
immunization services
2. Using the opportunity provided by measles immunization
activities to target rubella-susceptible populations
3. Strengthening surveillance systems by vigorous case
investigation and laboratory confirmation for measles,
rubella and congenital rubella syndrome
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4. Ensuring protection to women of childbearing age by
providing high coverage with one dose of rubella vaccine
5. Improving the availability of high-quality information to
health professionals and the public on the benefits and risks
of immunization against measles and rubella.
Immunization
Immunization is the most effective way to prevent and
control measles.  For successful measles control, immunization
of at least 95% of susceptible individuals with a two-dose
schedule is required8.  Efficacy of a single dose of measles vaccine
exceeds 90%9.  Following a second dose of measles vaccine,
efficacy levels exceed 99%9, 10.
Following media publicity surrounding a report published
in 1998 claiming a link between MMR (measles, mumps and
rubella) vaccination and autism
11, public confidence in some countries such as the UK has
been undermined 12, 13.  Findings of subsequent epidemiological
studies have shown no link between vaccination and
autism14-16.  No regulatory body in the world has changed its
policy as a result of this hypothesized link.
Surveillance
An adequately functioning surveillance system depends on
medical practitioners reporting all cases of measles to the
regional or national surveillance institutions.  Case-based
surveillance data are transferred to the European surveillance
of vaccine-preventable diseases network, EUVAC.NET, based
at the Statens Serum Institut in Copenhagen 17.  The network
involves surveillance institutions in the 15 European Union
countries, plus Iceland, Norway, Switzerland and Malta.
Another European network, CCEE-Baltic Network that is based
at the National Institute of Hygiene in Warsaw, involves central
and eastern European countries, the Baltic States and Turkey18.
Measles surveillance data are collected and analysed for the
purposes of describing the epidemiology of measles in the
participating countries.  The networks collaborate with the
World Health Organization in its efforts to implement the
strategies for measles elimination in the European Region.
Measles in Malta
The measles vaccine was first made available in Malta in
1982, and as the combined MMR vaccine in 1987.  It was initially
incorporated in the National Childhood Immunization Schedule
in 1982, and continued as MMR immunization from 1990
onwards.  The local Advisory Committee for Immunization
Policy currently recommends the first dose of MMR vaccine to
be given at 15 months and the second dose at 5-7 years of age.
Measles vaccination coverage for the first dose of MMR for
children born in 2001 has reached 90%.  In a recently started
school catch-up MMR vaccination campaign for the second
dose, 29% of children in their fifth year of school (aged 10 and
11 years) were vaccinated 19. Although measles vaccination may
be under-reported, it is believed that the vaccination coverage
for the first measles dose is still under the 95% required for
successful measles control.
Measles is a notifiable disease and medical practitioners are
obliged to report all cases of measles to the Disease Surveillance
Unit of the Department of Public Health.  The Unit sends case-
based reports of all notifed measles on a monthly basis to the
European surveillance network EUVAC.NET.
Following the introduction of the measles vaccine in Malta,
there has been a marked reduction in the number of reported
measles cases (Figure 1).  In 2002, there were seven reported
measles cases: three were in the 5-9 year age group, another
three in the 1-4 year age group and one case was aged less than
1 year. None of the cases were however, laboratory confirmed.
No complications from measles infection were reported.
Conclusion
Interrupting indigenous measles transmission and
preventing congenital rubella infection in the European Region
will require that each country strengthen its routine
immunization and surveillance programs.  The importance of
strengthening surveillance systems by vigorous case
investigation is critical to monitor progress toward measles
elimination in the Region.  Apart from the collection of
additional data on measles cases reported under routine
surveillance, enhanced surveillance also requires timely national
case-based reporting on at least a monthly basis.  In addition,
as vaccination coverage increases and measles reaches a near-
elimination phase in Europe, it becomes increasingly important
to investigate even suspected cases.  Hence, rapid laboratory
confirmation is an essential tool of enhanced surveillance.  Such
high quality surveillance is crucial to monitor trends, identify
the target population of vaccination programmes and determine
whether coverage objectives are being reached.  The
maintenance of enhanced surveillance and optimal vaccination
coverage are the cornerstones of the measles elimination plan
for the European Region by 2010.
Figure 1: Number of reported measles cases
in Malta, 1979-2002
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